Multicenter evaluation of Verigene Enteric Pathogens Nucleic Acid Test for detection of gastrointestinal pathogens

Kosuke Kosai1,*, Hiromichi Suzuki2, Kiyoko Tamai3, Yuya Okada1, Norihiko Akamatsu1, Atsuo Ueda4, Shigeyuki Notake4, Yuji Yaguchi3 & Katsunori Yanagihara1,5

We investigated the efficiency of the Verigene Enteric Pathogens Nucleic Acid Test (Verigene EP test), which is an automated microarray-based assay system that enables rapid and simultaneous genetic detection of gastrointestinal pathogens and toxins, including those in the Campylobacter Group, Salmonella species, Shigella species, the Vibrio Group, Yersinia enterocolitica, Shiga toxin 1 and 2, norovirus GI/GII, and rotavirus A. Three clinical laboratories evaluated the Verigene EP test, using 268 stool samples for bacterial and toxin genes and 167 samples for viral genes. Culture-based reference methods were used for the detection of bacteria and toxins, while a different molecular assay was used for viral detection. The overall concordance rate between the Verigene EP test and the reference methods for the 1940 assays was 99.0%. The overall sensitivity and specificity of the Verigene EP test were 97.0% and 99.3%, respectively. Of the 19 samples with discordant results, 13 samples were false positives and six were false negatives. The Verigene EP test simultaneously detected two targets in 11 samples; overall, the test demonstrated high efficiency in detecting crucial diarrheagenic pathogens, indicating its suitability for clinical practice.

Acute infectious diarrhea is a major cause of outpatient visits and hospitalization1. Since most diarrheal illnesses are self-limited, microbiological testing is not necessary for all patients. However, rapid etiological identification is required for those with serious symptoms and conditions such as systemic illness, fever, and bloody stool2, to enable effective antimicrobial treatment against specific pathogens. Furthermore, because some patients with infectious diarrhea should be isolated to prevent pathogen transmission in hospitals, more prompt and accurate methods are needed to detect crucial gastrointestinal pathogens.

The Verigene Enteric Pathogens Nucleic Acid Test (Verigene EP test) (Luminex Corporation) is an automated system based on microarray technology that enables simultaneous detection of enteric pathogens faster (3 h or less, including handling time) than conventional stool culture3. Since only a few previous studies have investigated the utility of this test3,4, and epidemiological differences affect the performance of diagnostic methods5, we conducted a multicenter evaluation in Japan to assess the ability of the Verigene EP test to detect crucial enteric pathogens.

Materials and methods

Study design. We examined clinical stool samples submitted to laboratories at the Nagasaki University Hospital, Tsukuba Medical Center Hospital, and Miroku Medical Laboratory between October 2016 and March 2018. The assay for this study was performed soon after routine testing or using samples stored at −80 °C.

All research was performed in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects, which was issued by the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare. Informed consent was obtained using the opt-out method provided on the website. The Institutional Review Board of Nagasaki University Hospital approved this study (approval number 16062725/18070902).

1Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki 852-8501, Japan. 2Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, Ibaraki, Japan. 3Miroku Medical Laboratory Inc., Nagano, Japan. 4Department of Clinical Laboratory, Tsukuba Medical Center Hospital, Ibaraki, Japan. 5Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. *email: k-kosai@nagasaki-u.ac.jp
**Verigene EP test.** The Verigene EP test, which has been approved for use in clinical settings by the Food and Drug Administration (FDA) in the United States and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, was used according to the manufacturer’s instructions. The test requires a processor, a reader, and single-use consumables. To prepare the fecal suspension for the assay, a swab dipped into stool was mixed with Stool Prep Buffer for 15–20 s using a vortex mixer. Extraction Tray, Tip Holder Assembly, Amplification Tray, and Test Cartridge were loaded into the processor. After centrifugation, 200 μL of the suspension was loaded into the Sample Loading Well of the Extraction Tray. Nucleic acid extraction, amplification, and nanoparticle-based microarray hybridization were automatically performed on the processor, and the data were analyzed by the reader. The Verigene EP test is aimed at the genetic detection of *Campylobacter* Group (C. *jejuni*, *coli*, and *lari*), *Salmonella* species, *Shigella* species (*s. boydii*, *sonnei*, *flexneri*, and *dyesseritae*), *Vibrio* Group (V. *cholerae* and *parahaemolyticus*), *Versinia enterocolitica*, Shiga toxin (Stx) 1 and 2, norovirus GI/GII, and rotavirus A*13,14,15*. The test does not target protozoa.

**Culture methods.** Culture-based methods for the detection of bacteria and toxins were performed based on the guidelines for the diagnostic testing of enteric infections, textbooks, and the manufacturer’s instructions. The media used and the identification methods are listed in Supplemental Table 1. We did not use enrichment broth for the cultures. In addition to cultures, reversed passive latex agglutination, and enzyme immunoassay were used for detecting Shiga toxins.

**xTAG Gastrointestinal Pathogen Panel.** The assay was performed with the FDA-approved xTAG Gastrointestinal Pathogen Panel (GPP) (Luminex Corporation), according to the manufacturer’s instructions. xTAG GPP requires prior nucleic acid extraction, multiplex amplification, and bead hybridization; the test can detect the genes of 15 gastrointestinal pathogens and toxins (nine bacteria and toxins, three viruses, and three protozoa), with several recent studies validating its performance*10–12*. An inoculating loop dipped into stool or 100 μL of watery diarrheal stool was added to a Bertin SK38 Soil Grinding Lysis Bead Tube with NucliSENS easyMAG Lysis Buffer (bioMérieux) or ASL Lysis Buffer (Qiagen). Ten μL of xTAG MS2 (internal control) was added, except in the negative control tube. The tube was mixed for 5 min using a vortex mixer, settled at room temperature for 10–15 min, and centrifuged at 14,000 rpm for 2 min. 200 μL of the supernatant was removed from the middle of the layer and used for nucleic acid extraction, using the QiAamp MinElute Virus Spin Kit (Qiagen) according to the manufacturer’s instructions. Ten μL of the nucleic acid sample was mixed with 15 μL of prepared multiplex PCR master mix, and the PCR reactions were performed under the following conditions: 20 min at 53 °C, 15 min at 95 °C, 38 cycles consisting of 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C, and 2 min at 72 °C for the final extension. Five μL of the PCR product was mixed with 20 μL xTAG GPP Bead Mix and 75 μL xTAG SAPE (Streptavidin, R-Phycocerythrin Conjugate) diluted 75 times with xTAG Reporter Buffer. Bead hybridization was performed under the following conditions: 3 min at 60 °C and 45 min at 45 °C. Data were analyzed using the xTAG Data Analysis Software LSM version 2.00 after data acquisition using the MAGPIX System*13*.

**Multiplex real-time PCR.** Multiplex real-time PCR assay for viral detection was performed by BML, INC. as follows*14,15*. Briefly, a 10% (wt/vol) stool suspension was prepared with distilled sterile water and centrifuged at 3000×g for 20 min. Nucleic acid was extracted from 140 μL of the stool suspension using NucleoMag (Takara Bio Inc.) or QIAamp Virus RNA Mini Kit (Qiagen) according to the manufacturer’s instructions. The extracted nucleic acid was eluted with 60 μL of diethyl pyrocarbonate-treated water and stored at −80 °C until use. After reverse transcription using PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio Inc.) according to the manufacturer’s instructions, multiplex PCR was performed using the QuantiTect Multiplex PCR kit (Qiagen) on a LightCycler 480 System (Roche Diagnostics). Amplification was carried out in 50 μL reaction mixture containing 5 μL nucleic acid sample. The reaction steps were as follows: 15 min at 95 °C and 40 cycles consisting of 1 min at 94 °C and 90 s at 60 °C. Primers and probes for the detection of norovirus GI/GII and rotavirus A genes have been described elsewhere*14,15*.

**Reference methods and discrepant analysis.** Culture-based methods were used as reference methods for the detection of bacteria and toxins. The xTAG GPP was used as a reference method for viral detection. For the detection of bacteria and toxins, a discrepant analysis was performed by re-examination using the Verigene EP test for the samples with false-negative results or by the assay using the xTAG GPP for the samples with false-positive results. Discrepant analysis for each virus was performed using multiplex real-time PCR.

**Efficiency of the Verigene EP test.** We calculated the sensitivity and specificity of the Verigene EP test in detecting targets, based on results from the reference methods, and determined the 95% confidence intervals using the software R version 3.5.1*16*. We determined the limit of detection (LoD) of the Verigene EP test. The LoD information was provided by the LumineX Corporation, and the LoD used in this study was 1.11 × 10⁵ colony-...
forming units (CFU)/mL, which was the highest LoD among Shigella species. The concentration of the bacterial suspension was adjusted using the McFarland turbidity standard. Serial dilutions of bacterial suspensions were plated onto agar medium, and the actual concentration was calculated by counting the number of bacterial colonies.

Results
Detection ability of Verigene EP test for clinical stool samples. We examined 268 clinical stool samples for bacteria and toxins (266 samples for Stx 1 and 2) and 167 samples for viruses. Of the 268 samples tested for bacteria and toxins and the 167 samples tested for viruses, 266 and 160 samples respectively (95.5% and 95.8%) had fully concordant results between the Verigene EP test and the reference methods. Table 1 depicts the detection ability of the Verigene EP test for clinical samples as compared to the reference methods. The overall sensitivity and specificity of the test were 97.0% (195/201) and 99.3% (1726/1739), respectively. The sensitivity ranged from 87.5% for rotavirus (7/8) to 100.0% for the Campylobacter Group (47/47), Shigella species (2/2), Y. enterocolitica (16/16), and Stx 1 and 2 (25/25). Similarly, the specificity ranged from 97.7% for norovirus GI/GII (126/129) to 100.0% for Shigella species (266/266) and the Vibrio Group (259/259).

Of the 19 samples with discordant results, 13 and six were false positives and false negatives, respectively. Seven of the 13 false-positive samples were positive, and one out of the six false-negative samples was negative in the discrepant analysis (Table 1).

The Verigene EP test simultaneously detected two targets in 11 samples (Table 2). Of these 11 samples, five samples showed fully concordant results between the Verigene EP test and the reference methods, whereas six samples exhibited partial concordance between the two (Table 2).

| Pathogen and toxin gene | TP | TN | FP | FN | Sensitivity (%) | Specificity (%) |
|-------------------------|----|----|----|----|----------------|-----------------|
| **Bacterium**           |    |    |    |    |                |                 |
| Campylobacter Groupa    | 47 | 219| 2d | 0  | 100.0 (92.5–100.0) | 99.1 (96.8–99.9) |
| Salmonella species      | 53 | 211| 1* | 3* | 94.6 (85.1–98.9)  | 99.5 (97.4–100.0) |
| Shigella speciesb       | 2  | 266| 0  | 0  | 100.0 (15.8–100.0) | 100.0 (98.6–100.0) |
| Vibrio Groupc          | 8  | 259| 0  | 3* | 88.9 (51.8–99.7)  | 100.0 (98.6–100.0) |
| V. enterococitica       | 16 | 249| 3* | 0  | 100.0 (79.4–100.0) | 98.8 (96.6–99.8) |
| Shiga toxin 1 and 2     | 25 | 239| 2b | 0  | 100.0 (86.3–100.0) | 99.2 (97.0–99.9) |
| **Virus**               |    |    |    |    |                |                 |
| Norovirus G1/GII        | 37 | 126| 3d | 1* | 97.4 (86.2–99.9)  | 97.7 (93.4–99.5) |
| Rotavirus A             | 7  | 157| 2b | 3* | 87.5 (47.3–99.7)  | 98.7 (95.5–99.8) |
| Overall                 | 195| 1726|13 | 6  | 97.0 (93.6–98.9)  | 99.3 (98.7–99.6) |

**Table 1.** Efficiency of the Verigene Enteric Pathogens Nucleic Acid Test to detect pathogens and toxin genes for clinical stool samples. Data were compared to reference methods and expressed as numbers or percentages (95% confidence interval). TP true positive, TN true negative, FP false positive, FN false negative.

- Campylobacter jejuni, coli, and lari.
- Shigella boydii, sonnei, flexneri, and dysenteriae.
- Vibrio cholerae and parahaemolyticus.

All samples were positive in the discrepant analysis.

All samples were positive in re-examination using the Verigene EP test.

One sample was positive and two samples were negative in the discrepant analysis.

One sample was positive and the other was negative in the discrepant analysis.

Detection by Verigene EP test | Detection by reference methods | Results of discrepant analysis
--- | --- | ---
Campylobacter Group and Salmonella species | Campylobacter Group and Salmonella species | –
Campylobacter Group and Vibrio Group | Campylobacter Group and Vibrio Group | –
Campylobacter Group and rotavirus A | Campylobacter Group only | Negative for rotavirus A
Salmonella species and Y. enterocolitica | Salmonella species only | Positive for Y. enterocolitica
Salmonella species and norovirus GI/GII | Salmonella species and norovirus GI/GII | –
Vibrio Group and Y. enterocolitica | Vibrio Group only | Negative for Y. enterocolitica
Vibrio Group and Shiga toxin | Vibrio Group only | Positive for Shiga toxin
Y. enterocolitica and Shiga toxin | Y. enterocolitica only | Negative for Shiga toxin
Shiga toxin and norovirus | Shiga toxin and norovirus | –
Y. enterocolitica and norovirus GI/GII | Y. enterocolitica and norovirus GI/GII | –
Y. enterocolitica and norovirus GI/GII | Norovirus GI/GII only | Negative for Y. enterocolitica

**Table 2.** Detection of multiple targets by the Verigene Enteric Pathogens Nucleic Acid Test and comparative analysis.
Detection ability of Verigene EP test for characterized stool samples. Since the clinical stool samples included only two samples positive for *Shigella* species, we assessed the ability of Verigene EP test to detect the pathogens using characterized stool samples. We used 26 *Shigella sonnei* strains, which were previously isolated and stored in our institutions, and 13 strains were used in the preparation of characterized stool samples with concentrations targeting twice or 20 times the LoD of the Verigene EP test. The actual bacterial concentrations of these samples were $0.1 \rightarrow 2.6 \times 10^5$ CFU/mL or $5.0 \times 10^4 \rightarrow 1.0 \times 10^5$ CFU/mL. Of the 26 characterized samples examined, the Verigene EP test correctly detected *S. sonnei* in 25 samples, except for one sample with a bacterial concentration of $2.6 \times 10^5$ CFU/mL.

Discussion

Our study results demonstrated that the Verigene EP test accurately detected the genes of enteric pathogens and toxins in clinical samples with high sensitivity and specificity, which is consistent with previous reports. Due to the ability of the test to detect multiple targets in a single assay, the Verigene EP test can avoid overlooking any crucial gastrointestinal pathogens. Furthermore, the Verigene EP test enables rapid diagnosis with less work or training for laboratory technicians; on the other hand, conventional bacterial cultures are labor- and time-intensive. Additionally, unnecessary use of antimicrobial drugs and the duration of patient isolation may be reduced because of rapid diagnosis. A previous study reported that the xTAG GPP for gastrointestinal pathogens increased laboratory testing costs but decreased total costs for hospitalization by reducing patient isolation days. The Verigene EP test might have similar effects; however, further studies are required.

While the Verigene EP test showed 19 discrepant results compared to the reference methods, the discrepant analysis proved that the Verigene EP test might have provided true results, at least in some samples with discrepant results. If bacteria were detected by molecular method but not cultured, we should recognize both possibilities; that the results of molecular methods may be false positives and that the sensitivity of cultures is lower than that of molecular methods. A previous study described that the culture method failed to detect *Campylobacter* in 30% of positive clinical samples compared to non-cultural methods, including molecular assays. Additionally, if the xTAG GPP was not the best test in some cases, as described previously, the false-positive results of the Verigene EP test could result from the false-negative results of the xTAG GPP in the discrepant analysis.

Although each institution needs to consider how best to use the Verigene EP test effectively in daily practice, the test may be suitable used for community-acquired diarrhea requiring hospitalization to rapidly screen unmissable pathogens. Conversely, for hospital-acquired diarrhea, we might have to initially perform the Verigene *Clostridium difficile* nucleic acid test, which is a separate test for a single pathogen and performed using the same Verigene System.

This study has some limitations. First, we could not adequately assess the ability of this test to detect *Shigella* species in clinical samples because the number of positive samples was limited. Instead, the Verigene EP test could successfully detect *S. sonnei* in characterized stool samples, and previous studies reported that the sensitivity and specificity of the Verigene EP test for the detection of *Shigella* species was 87.5–95.4% and 99.1–99.8%, respectively. Furthermore, because we did not collect patient information and did not test all samples submitted to our laboratories during the study period, we could not validate the pathogenicity of the detected pathogens and the incidence of infections. Reportedly, some Stx 1 and 2 subtypes are linked to mild diseases or are rarely involved in human diseases. Finally, for detecting bacteria and toxins, we could not assess the efficiency of the Verigene EP test compared to other molecular assays because another molecular method was used only for the discrepant analysis.

In conclusion, the Verigene EP test is useful for detecting crucial diarrheagenic pathogens, and may have applications in daily clinical practice. Further studies are needed to establish practical diagnostic strategies for the complementary use of molecular assays and traditional methods.

Received: 21 August 2020; Accepted: 20 January 2021
Published online: 04 February 2021

References

1. Riddle, M. S., DuPont, H. L. & Connor, B. A. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. *Am. J. Gastroenterol*. **111**, 602–622 (2016).
2. Thielman, N. M. & Guerrant, R. L. Clinical practice. Acute infectious diarrhea. *N. Engl. J. Med*. **350**, 38–47 (2004).
3. Huang, R. S. et al. Performance of the Verigene® enteric pathogens test, Biofire FilmArray gastrointestinal panel and Luminex xTAG® gastrointestinal pathogen panel for detection of common enteric pathogens. *Diagn. Microbiol. Infect. Dis*. **86**, 336–339 (2016).
4. Beckman, A. K. & Ferrieri, P. Prospective investigation of an automated PCR/nucleic acid microarray-based platform for enteric pathogen testing. *Lab. Med.* **50**, 390–395 (2019).
5. LalKhen, A. G. & McCluskey, A. Clinical tests: sensitivity and specificity. *Cont. Educ. Anaesth. Crit. Care Pain* **8**, 221–223 (2008).
6. Reddington, K., Tuite, N., Minogue, E. & Barry, T. A current overview of commercially available nucleic acid diagnostics approaches to detect and identify human gastroenteritis pathogens. *Biomol. Detect. Quantif*. **1**, 3–7 (2014).
7. Leber, A. L. *Clinical Microbiology Procedures Handbook* 4th edn. (ASM Press, Washington, 2016).
8. The committee for developing guides on the laboratory test methods. Guidelines for the diagnostic testing of enteric infections. *The Japanese Society for Clinical microbiology* (2010) (in Japanese).
9. Oguri, T. *Clinical Microbiology Test Handbook* 4th edn. (Miwa-Shoten, Tokyo, 2011) (in Japanese).
10. Navidad, J. F., Griswold, D. J., Gradus, M. S. & Bhattacharyya, S. Evaluation of Luminex xTAG gastrointestinal pathogen analytic-specific reagents for high-throughput, simultaneous detection of bacteria, viruses, and parasites of clinical and public health importance. *J. Clin. Microbiol*. **51**, 3018–3024 (2013).
11. Khare, R. et al. Comparative evaluation of two commercial multiplex panels for detection of gastrointestinal pathogens by use of clinical stool specimens. *J. Clin. Microbiol*. **52**, 3667–3673 (2014).
12. Smieja, M. & Goldfarb, D. M. Molecular detection of diarrheal pathogens. *Clin. Microbiol. Newsl*. **38**, 137–145 (2016).
13. Vocale, C. et al. Comparative evaluation of the new xTAG GPP multiplex assay in the laboratory diagnosis of acute gastroenteritis. Clinical assessment and potential application from a multicentre Italian study. *Int. J. Infect. Dis.* **34**, 33–37 (2015).

14. Kageyama, T. et al. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. *J. Clin. Microbiol.* **41**, 1548–1557 (2003).

15. Tadokoro, K., Yamaguchi, T. & Shinohara, M. Development of comprehensive detection method for viruses causing contagious gastroenteritis using multiplex real-time PCR. *Rinsho to Biseibutsu (Clinical Microbiology)* **36**, 251–256 (2009) (in Japanese).

16. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/ (2018).

17. Goldenberg, S. D., Bacelar, M., Brazier, P., Bisnauthsing, K. & Edgeworth, J. D. A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients. *J. Infect.* **70**, 504–511 (2015).

18. Vanniasinkam, T., Lanser, J. A. & Barton, M. D. PCR for the detection of *Campylobacter* spp. in clinical specimens. *Lett. Appl. Microbiol.* **28**, 52–56 (1999).

19. de Boer, R. F., Ott, A., Keszytyus, B. & Kooistra-Smid, A. M. Improved detection of five major gastrointestinal pathogens by use of a molecular screening approach. *J. Clin. Microbiol.* **48**, 4140–4146 (2010).

20. Buss, S. N. et al. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. *J. Clin. Microbiol.* **53**, 915–925 (2015).

21. Buss, J. E. et al. *Campylobacter* culture fails to correctly detect *Campylobacter* in 30% of positive patient stool specimens compared to non-cultural methods. *Eur. J. Clin. Microbiol. Infect. Dis.* **38**, 1087–1093 (2019).

22. Kosai, K. et al. Performance evaluation of the Verigene® *Clostridium difficile* nucleic acid test, an automated multiplex molecular testing system for detection of *C. difficile* toxin. *J. Infect. Chemother.* **23**, 674–677 (2017).

23. Melton-Celsa, A. R. Shiga Toxin (Stx) classification, structure, and function. *Microbiol. Spectr.* **2**, EHEC-0024-2013 (2014).

**Author contributions**
K.K., H.S., K.T., and K.Y. contributed to the conception and design of the study. Y.O., N.A., A.U., S.N., and Y.Y. performed the experiments and collected the data. K.K. drafted the manuscript, and H.S. and K.T. revised the manuscript. All authors agreed to all aspects of the work and approved the manuscript for publication.

**Competing interests**
Reagents, instrumentation, and funding were provided by Hitachi High-Tech Corporation. K.K. has received honoraria from Luminex Japan Corporation Ltd. K.Y. has received honoraria from Hitachi High-Tech Corporation and Luminex Japan Corporation Ltd. H.S., K.T., Y.O., N.A., A.U., S.N., and Y.Y. declare no other conflict of interest.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-82490-z.

Correspondence and requests for materials should be addressed to K.K.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021